Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31284031 | 0.92 | CA12 (0.59) | DGKATDP1CA12CA1CA2 | |
| SCHEMBL13019153 | 0.88 | CA12 (0.55) | DGKATDP1CA12CA1CA2 | |
| SCHEMBL31065300 | 0.88 | CA12 (0.55) | DGKATDP1CA12CA1CA2 | |
| SCHEMBL19227176 | 0.87 | DGKA (0.53) | DGKADNM1EPHX2ACHEPAM | |
| SCHEMBL15613905 | 0.87 | CA12 (0.54) | DGKATDP1CA12CA1CA2 | |
| SCHEMBL20589930 | 0.85 | CA12 (0.59) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL28969493 | 0.85 | CA12 (0.55) | DGKATDP1CA12CA1CA2 | |
| SCHEMBL12999572 | 0.85 | CA12 (0.51) | DGKATDP1CA12CA1CA2 | |
| SCHEMBL15015919 | 0.85 | TDP1 (0.61) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL3312317 | 0.85 | TDP1 (0.49) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073473-B1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-10-17 | — | — | EP | disclosed |
| US-20040146462-A1 | Ultrasonic visualisation of perfusion in the myocardium and other tissues is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration | GE HEALTHCARE AS (NO) | 2004-07-29 | — | — | US | disclosed |
| EP-1073473-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | Marsden, John Christopher (GB) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999053963-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | MARSDEN, JOHN, CHRISTOPHER (GB) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040146462-A1 | Ultrasonic visualisation of perfusion in the myocardium and other tissues is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration | TNNC1, TNNI3, FABP3 | DGKA 34/4885TDP1 3731/4885DNM1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.